Advertisement

Phase I/II Trial of High-Dose Cytosine Arabinoside and Mitoxantrone in Adult Refractory Acute Myeloid Leukemia

  • W. Hiddemann
  • H. Kreutzmann
  • K. Straif
  • W. D. Ludwig
  • H.-J. Fuhr
  • R. Donhuijsen-Ant
  • E. Lengfelder
  • T. Büchner
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 30)

Abstract

In spite of a high initial response rate of 60% –80% the vast majority of adult patients with acute myeloid leukemia (AML) still cannot be cured of the disease and ultimately die from recurrent and refractory leukemia. The development of new therapeutic approaches and of more effective drugs therefore seems warranted.

Keywords

Acute Myeloid Leukemia Acute Leukemia Refractory Acute Myeloid Leukemia High Dose Cytosine Arabinoside Refractory Leukemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Amadori S, Papa G, Avvisati G, Fenu S, Monarca B, Petti MC, Pulsoni A, Mandelli F (1984) Sequential combination of high dose Ara-C (HiDAC) and asparaginase ( ASP) for the treatment of advanced acute leukemia and lymphoma. Leuk Res 8: 729–735Google Scholar
  2. 2.
    Arlin ZA, Silver R, Cassileth P, Armentrout S, Moore J, Dhagestani A, Coleman M, Schoch I, Posner L (1984) Phase I—II trial of mitoxantrone in acute leukemia. Proc Am Ass Cancer Res 25: 189Google Scholar
  3. 3.
    Büchner TH, Urbanitz D, Emmerich B, Fischer JT, Fülle HH, Heinecke A, Hossfeld DK, Koeppen KM, Labedzki L, Löffler H, Nowrousian MR, Pfreundschuh M, Pralle H, Rühl H, Wendt FC (1982) Multicentre study on intensified remission induction therapy for acute myeloid leukemia. Leuk Res 6: 827–831PubMedCrossRefGoogle Scholar
  4. 4.
    Büchner TH, Urbanitz D, Hiddemann W, Rühl H, Ludwig WD, Fischer J, Aul HC, Vaupel HA, Kuse R, Zeile G, Nowrousian MR, König HJ, Walter M, Wendt FC, Sodomann H, Hossfeld DK, von Paleske A, Löffler H, Gassmann W, Hellriegel KP, Fülle HH, Lunscken C, Emmerich B, Pralle H, Pees HW, Pfreundschuh M, Bartels H, Koeppen KM, Schwerdtfeger R, Donhuijsen-Ant R, Mainzer K, Bonfert B, Köppler H, Zurborn KH, Ranft K, Thiel E, Heinecke A (1985) Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol 3: 1583–1589PubMedGoogle Scholar
  5. 5.
    Capizzi RL, Poole M, Cooper MR, Richards F II., Stuart JJ, Jackson DVJR, White DR, Spurr CL, Hopkins JO, Muss HB, Rudnick SA, Wells R, Gabriel D, Ross D (1983) Treatment of poor risk acute leukemia with sequential high-dose Ara-C and asparaginase. Blood 63: 694–700Google Scholar
  6. 6.
    Colly LP, Hagenbeek T (1977) Experimental chemotherapy: a rat model for human acute myeloid leukemia. In: Baum JS, Ledney GD (eds) Experimental Hematology Today. Springer, Berlin Heidelberg New York, pp 211–219Google Scholar
  7. 7.
    Early AP, Preisler HD, Slocum H, Rustum YM (1982) A pilot study of high dose 1-ß-Dfuranosylcytosine for acute leukemia and refractory lymphoma. Cancer Res 42: 15871594Google Scholar
  8. 8.
    Estey EH, Keating MJ, McCredie KB, Bodey GP, Freireich EJ (1983) Phase II trial of mitoxantrone in refractory acute leukemia. Cancer Treat Rep 67: 389–390PubMedGoogle Scholar
  9. 9.
    Fountzilas G, Ohnuma T, Okano T, Greenspan EM, Holland JF (1983) Schedule-dependent synergism of cytosine arabinoside (Ara-C) with mitoxantrone in human acute myelogenous leukemia cell line HL-60. Proc Am Soc Clin Oncol 2: 179Google Scholar
  10. 10.
    Herzig RH, Wolff SN, Lazarus HM, Phillips GL, Karanes C, Herzig GP (1983) High-dose cytosine arabinoside therapy for refractory leukemia. Blood 62: 361–369PubMedGoogle Scholar
  11. 11.
    Herzig RH, Lazarus HM, Wolff SN, Phillips GL, Herzig GP (1985) High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia. J Clin Oncol 3: 992–997PubMedGoogle Scholar
  12. 12.
    Hiddemann W, Urbanitz D, Grüner A, Büchner TH (1985) Hochdosis Cytosin-Arabinosid und Mitoxantron in Kombination bei refraktärer akuter myeloischer Leukämie: Konzept einer Phase I/II Studie. Fortschr antimikrobiol antineopl Chemother 4–2: 485489Google Scholar
  13. 13.
    Hiddemann W, Kreutzmann H, Ludwig WD, Aul HC, Donhuijsen-Ant R, Lengfelder E, Büchner TH (1985) Mitozantrone and high dose cytosine arabinoside in refractory acute myeloid leukemia. Lancet I1: 508CrossRefGoogle Scholar
  14. 14.
    Hines JD, Oken MM, Mazza JJ, Keller AM, Streeter RR, Glick JH (1984) High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia. J Clin Oncol 2: 545–549PubMedGoogle Scholar
  15. 15.
    Meyer P, Ho AD, Ehninger G, Mjaaland I, Heidemann E, Seither E (1985) Mitoxantrone in the treatment of relapsed and refractory acute leukemia. J Invest New Drugs 3: 203206Google Scholar
  16. 16.
    Mitrou PS, Kuse R, Anger H, Herrmann R, Bonfert B, Pralle H, Thiel E, Westerhausen M, Mainzer K, Bartels H, Löffler H (1985) Aclarubicin (aclacinomycin A) in the treatment of relapsing leukaemias. Europ J Cancer Clin Oncol 21: 919–923PubMedCrossRefGoogle Scholar
  17. 17.
    Ohnuma T, Rosner F, Levy RN, Cuttner J, Moon JH, Silver RT, Blom J, Falkson G, Burningham R, Glidewell O, Holland JF (1974) Treatment of adult leukemia with Lasparaginase. Cancer Chemother Rep 55: 269–275Google Scholar
  18. 18.
    Paciucci PA, Cuttner J, Holland JF (1984) Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia. Sem Oncol 11, Suppl 1: 36–40Google Scholar
  19. 19.
    Prentice HG, Robbins G, Ma DDF, Ho AD (1984) Mitoxantrone in relapsed and refractory acute leukemia. Sem Oncol 11, Suppl 1: 32–35Google Scholar
  20. 20.
    Rudnick SA, Cadman EC, Capizzi RL, Skeel RT, Bertino JR, McIntosh S (1979) High dose cytosine arabinoside ( HDARAC) in refractory acute leukemia. Cancer 44: 1189–1193Google Scholar
  21. 21.
    Wells RJ, Feusner J, Devny R, Woods W, Provisor AJ, Cairo MS, Odom LF, Nachman J, Jones GR, Ettinger LJ, Capizzi RL (1983) Sequential high-dose cytosine arabinoside-asparaginase treatment in advanced childhood leukemia. J Clin Oncol 3: 998–1004Google Scholar
  22. 22.
    Willemze R, Zwaan FE, Colpin G, Keuning JJ (1982) High dose cytosine arabinoside in the management of refractory acute leukemia. Scand J Haematol 29: 141–146PubMedCrossRefGoogle Scholar
  23. 23.
    World Health Organization (1979) WHO handbook for reporting results of cancer treatment. WHO publication 38, GenevaGoogle Scholar
  24. 24.
    Yamada K, Nakamura T, Tsuruo T, Kitahara T, Mackawa T, Uzaka Y, Kurita S, Masaoka T, Takaku F, Hirota Y, Amaki I, Osamura S, Ito M, Nakano M, Oguro M, Inagaki J, Unozawa K (1980) A phase II study of aclacinomycin-A in acute leukemia in adults. Cancer Treat Rev 7: 177–182PubMedCrossRefGoogle Scholar
  25. 25.
    Yates J, Glidewell O, Wiernik P, Cooper MR, Steinberg D, Dosik H, Levy R, Hoagland C, Henry P, Gottlieb A, Cornell C, Berenberg J, Hutchinson JL, Raich P, Nissen N, Ellison RR, Frelick R, James GW, Falkson G, Silver RT, Haurani F, Green M, Henderson E, Leone L, Holland JF (1982) Cytosine arabinoside with daunorubicin or adriamycin for therapy for acute myelocytic leukemia: a CALGB study. Blood 60: 454–462PubMedGoogle Scholar
  26. 26.
    Zittoun R, Marie JP, Pochat L (1983) High-dose cytosine-arabinoside (Ara-C) alone or combined with m-AMSA for induction or consolidation-maintenance in acute myelogenous leukemia (AML). Proc 13th Int Congr Chemoth 216: 62–66Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • W. Hiddemann
    • 1
  • H. Kreutzmann
    • 2
  • K. Straif
    • 3
  • W. D. Ludwig
    • 4
  • H.-J. Fuhr
    • 5
  • R. Donhuijsen-Ant
    • 6
  • E. Lengfelder
    • 7
  • T. Büchner
    • 1
  1. 1.Departments of Internal MedicineUniv. of MünsterFederal Republic of Germany
  2. 2.Departments of Internal MedicineUniv. of Ev. Krh. Essen-WerdenFederal Republic of Germany
  3. 3.Departments of Internal MedicineUniv. of BonnFederal Republic of Germany
  4. 4.Departments of Internal MedicineUniv. of BerlinFederal Republic of Germany
  5. 5.Departments of Internal MedicineUniv. of MainzFederal Republic of Germany
  6. 6.Departments of Internal MedicineUniv. of St.-Joh.Hospital DuisburgFederal Republic of Germany
  7. 7.Departments of Internal MedicineUniv. of Mannheim-HeidelbergFederal Republic of Germany

Personalised recommendations